GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Summit Therapeutics SMMT · USD

Health Care · US listing · 🇺🇸 United States

Compare

17.84

+9.25%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

—

FY2015FY2024

Net income

−$221.3m

FY2015FY2024

Free cash flow

−$142.2m

FY2015FY2024

Shareholders' equity

$388.7m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue——$710,000$1.8m$860,000$740,000$57.1m$16.1m$2.3m—
Gross profit——————$43.0m$12.3m——
Research and development$150.8m$59.5m$51.1m$84.3m$52.0m$38.8m$50.9m$37.6m$18.9m$16.9m
Operating income−$211.0m−$88.7m−$63.6m−$86.2m−$52.3m−$27.5m$11.3m−$27.9m−$24.3m−$20.9m
Net income−$221.3m−$614.9m−$78.8m−$88.6m−$52.7m−$29.1m$9.9m−$26.4m−$21.4m−$20.1m
Diluted earnings per share-0.31-0.99-0.41-0.96-0.76-0.890.57-2.01-0.35-0.34

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$435.6m$202.9m$664.2m$113.4m$102.5m$96.2m$79.6m$78.2m$37.6m$25.1m
Cash and short-term investments$412.3m$186.2m$348.6m$71.8m$66.4m$63.8m$35.2m$28.5m$28.1m$16.3m
Total liabilities$46.8m$125.3m$537.5m$30.1m$23.0m$17.4m$23.8m$82.7m$41.1m$9.0m
Debt—$100.0m$514.3m————$4.4m$5.9m$5.0m
Shareholders' equity$388.7m$77.7m$126.7m$83.3m$79.5m$78.9m$55.8m−$4.5m−$3.5m$16.1m
Shares outstanding719m620m193m92m70m33m17m13m62m59m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$142.1m−$76.8m−$41.6m−$72.6m−$48.1m−$20.8m−$35.1m−$21.5m$12.1m−$17.2m
Capital spending−$139,000−$128,000−$620,000−$310,000−$420,000−$340,000−$160,000−$820,000−$90,000−$70,000
Free cash flow−$142.2m−$76.9m−$42.2m−$72.9m−$48.5m−$21.1m−$35.3m−$22.3m$12.1m−$17.3m

Latest quarters

By quarter end

Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Dec 2023Sept 2023Jun 2023
Operating income−$568.4m−$66.9m−$65.6m−$58.4m−$44.6m−$36.2m−$20.5m−$15.8m
Net income−$565.7m−$62.9m−$61.2m−$56.3m−$60.4m−$36.6m−$21.3m−$14.7m
Diluted earnings per share-0.76-0.09-0.08-0.08-0.09-0.05-0.03-0.02
Cash from operations−$66.0m−$61.0m−$48.0m−$30.0m−$33.0m−$19.0m−$14.0m−$29.0m
Total assets$324.0m$383.8m$435.6m$502.9m$341.9m$202.9m$218.5m$237.4m
Cash and short-term investments$297.9m$361.3m$412.3m$486.9m$325.5m$186.2m$198.9m$215.0m
Debt—————$100.0m$100.0m$100.0m
Shareholders' equity$259.4m$344.3m$388.7m$437.9m$195.1m$77.7m$99.4m$119.6m

Financial ratios

Data as of 1 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross margin———100.0%100.0%100.0%100.0%98.8%100.0%
Operating margin———-10420.1%-4882.3%-11392.7%35.2%9.4%-182.3%
Net margin———-11174.8%-4762.1%-6127.6%11.6%19.0%-142.3%
Return on equity-220.8%-56.9%-784.6%-63.1%-139.5%-66.0%———
Return on assets-193.6%-50.8%-300.3%-12.0%-102.5%-51.2%———
Free cash flow yield-1.8%-0.9%-0.5%-0.7%-3.3%-2.8%———
Revenue growth———-67.8%187.7%-98.5%-24.7%302.9%496.3%
Earnings growth510.7%-63.4%640.2%-24.4%123.6%-871.6%———
Current ratio9.87x10.15x9.30x16.93x3.80x4.41x———
Debt to equity0.01x0.01x1.66x4.96x0.01x0.00x———
Equity ratio87.7%89.3%38.3%19.1%73.5%77.5%———
Interest coverage—-20.78x-28.94x-13.81x-314.31x-280.96x363.01x——
R&D as a share of sales———7375.7%4718.2%6194.7%91.1%86.0%204.5%
Buybacks as a share of market value-3.9%-5.3%-155.0%-183.8%-28.7%-128.0%———

Growth per year

Compound annual rate

3 years5 years10 years
Operating income34.8%50.3%32.3%
Net income35.7%50.0%34.6%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings-37.0-1.7-6.7-1.8-2.1-0.60.7-0.4-1.6-2.3
Price to sales———87.7126.323.60.10.615.3—

Market value over time

31 Oct 2016 to 30 Sept 2026, in USD

$724.7m$13.16bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return57%534%-38%67%-16%308%24%-41%14%-21%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.